Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nnadozie Emechebe

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Preventing Chronic Disease|June 6, 2020
Using an Advanced Practice Pharmacist in a Team-Based Care Model to Decrease Time to Hemoglobin A<sub>1c</sub> Goal Among Patients With Type 2 Diabetes, Florida, 2017-2019Kevin Cowart, Wendy Updike, Nnadozie Emechebe, et al.
The American Journal of Managed Care|August 17, 2019
Passive social health surveillance and inpatient readmissionsNnadozie Emechebe, Pamme Lyons Taylor, Oluyemisi Amoda, et al.
Population Health Management|April 18, 2018
Expenditure Reductions Associated with a Social Service Referral ProgramZachary Pruitt, Nnadozie Emechebe, Troy Quast, et al.
Public Health Nutrition|May 22, 2019
Predictors of early childhood undernutrition in Nigeria: the role of maternal autonomyNgozichukwuka Agu, Nnadozie Emechebe, Korede Yusuf, et al.
JCO Oncology Practice|April 16, 2024
Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line SettingBita Fakhri, Nnadozie Emechebe, Beenish S Manzoor, et al.
British Journal of Haematology|July 25, 2024
Real-world comparative effectiveness of venetoclax-obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemiaNilanjan Ghosh, Beenish S Manzoor, Bita Fakhri, et al.
Contemporary Clinical Trials Communications|February 24, 2025
Demographic clinical trial diversity assessment methods: Use of real-world dataHua Chen, Nnadozie Emechebe, Sudeep Karve, et al.
The Annals of Pharmacotherapy|June 9, 2021
Measurement of Pharmacist-Physician Collaborative Care on Therapeutic Inertia in Patients With Type 2 DiabetesKevin Cowart, Nnadozie Emechebe, Rashmi Pathak, et al.
Journal of Dental Hygiene : JDH|May 2, 2020
Evaluation of an Automated Digital Scoring System of Dental PlaqueCindy L Munro, Zhan Liang, Nnadozie Emechebe, et al.
Journal of Managed Care & Specialty Pharmacy|July 24, 2024
Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline settingScott F Huntington, Beenish S Manzoor, Dureshahwar Jawaid, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Preventing Chronic Disease|June 6, 2020
Using an Advanced Practice Pharmacist in a Team-Based Care Model to Decrease Time to Hemoglobin A<sub>1c</sub> Goal Among Patients With Type 2 Diabetes, Florida, 2017-2019Kevin Cowart, Wendy Updike, Nnadozie Emechebe, et al.
The American Journal of Managed Care|August 17, 2019
Passive social health surveillance and inpatient readmissionsNnadozie Emechebe, Pamme Lyons Taylor, Oluyemisi Amoda, et al.
Population Health Management|April 18, 2018
Expenditure Reductions Associated with a Social Service Referral ProgramZachary Pruitt, Nnadozie Emechebe, Troy Quast, et al.
Public Health Nutrition|May 22, 2019
Predictors of early childhood undernutrition in Nigeria: the role of maternal autonomyNgozichukwuka Agu, Nnadozie Emechebe, Korede Yusuf, et al.
JCO Oncology Practice|April 16, 2024
Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line SettingBita Fakhri, Nnadozie Emechebe, Beenish S Manzoor, et al.
British Journal of Haematology|July 25, 2024
Real-world comparative effectiveness of venetoclax-obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemiaNilanjan Ghosh, Beenish S Manzoor, Bita Fakhri, et al.
Contemporary Clinical Trials Communications|February 24, 2025
Demographic clinical trial diversity assessment methods: Use of real-world dataHua Chen, Nnadozie Emechebe, Sudeep Karve, et al.
The Annals of Pharmacotherapy|June 9, 2021
Measurement of Pharmacist-Physician Collaborative Care on Therapeutic Inertia in Patients With Type 2 DiabetesKevin Cowart, Nnadozie Emechebe, Rashmi Pathak, et al.
Journal of Dental Hygiene : JDH|May 2, 2020
Evaluation of an Automated Digital Scoring System of Dental PlaqueCindy L Munro, Zhan Liang, Nnadozie Emechebe, et al.
Journal of Managed Care & Specialty Pharmacy|July 24, 2024
Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline settingScott F Huntington, Beenish S Manzoor, Dureshahwar Jawaid, et al.
Pageof 2